Vector Science & Therapeutics builds 15-patent intellectual property portfolio for therapeutic delivery

Mequon, Wis. – Vector Science & Therapeutics, Corp. announced the expansion of its intellectual property portfolio to 15 patent applications. Developed over approximately the past two years, these applications aim to establish a broad technology estate centered on precisely delivering therapeutic agents, including challenging peptides and biologics, to target tissues at the right concentration and duration.

The company's intellectual property strategy focuses on a portfolio of interconnected therapeutic delivery technologies rather than single drugs or indications. The patent applications cover non-invasive, minimally invasive, and locoregional systems designed to overcome biological, anatomical, and patient compliance barriers that limit conventional drug administration.

"We believe many promising therapeutic agents are constrained not simply by the molecule, but by the limitations of how that molecule reaches its intended target," said Tom Bachinski, Chief Technology Officer of Vector Science & Therapeutics. "Our intellectual property strategy is focused on the delivery problem. We are developing multiple technologies designed to move therapeutics across biological barriers, concentrate treatment at difficult-to-reach tissue and reduce unnecessary systemic exposure."

The technology portfolio encompasses areas such as multi-route peptide and biologic delivery, advanced transdermal delivery, electrically assisted deep-tissue transport, and localized administration systems. Key applications include novel approaches for pancreatic oncology, regenerative medicine, opioid-sparing pain management, and smart wound care.

Vector Science & Therapeutics aims to integrate drug formulation, delivery hardware, and sensing technologies to enable more precise and effective treatments, particularly for difficult-to-administer compounds like peptides.